Brain Function Improving Agent

Abstract

A novel agent useful for improving brain function is provided. The active ingredient in this agent is a Bifidobacterium breve and/or a Bifidobacterium breve -containing cultured material is provided.

1 . A composition for improving brain function comprising an active ingredient of a  Bifidobacterium breve  and/or a cultured material comprising  Bifidobacterium breve.    
     
     
         2 . The composition according to  claim 1  wherein the  Bifidobacterium breve  is  Bifidobacterium breve  MCC1274 (FERM BP-11175) and/or  Bifidobacterium breve  M-16V (BCCM LMG23729). 
     
     
         3 . The composition according to  claim 1  wherein said improving brain function comprises prevention, treatment, and/or improvement of symptoms or diseases resulting from a reduced brain function selected from the group consisting of dementia, depression, schizophrenia, delirium, amnesia, reduced ability to make decisions or judgements, or to think, cognitive decline, intellectual disability, and combinations thereof. 
     
     
         4 . The composition according to  claim 3  wherein said dementia is selected from the group consisting of Alzheimer's disease, dementia with Lewy bodies, frontotemporal dementia, cerebrovascular dementia, and combinations thereof. 
     
     
         5 . A pharmaceutical comprising the composition according to  claim 1 . 
     
     
         6 . The pharmaceutical according to  claim 5  comprising the  Bifidobacterium breve  at 1×10 6  to 1×10 12  CFU/g. 
     
     
         7 . A food or beverage product for improving brain function comprising a  Bifidobacterium breve  and/or a cultured material containing  Bifidobacterium breve -containing cultured material. 
     
     
         8 . A method for prevention, treatment, and/or improvement of symptoms or diseases resulting from a reduced brain function selected from the group consisting of dementia, depression, schizophrenia, delirium, amnesia, reduced ability to make decisions or judgements, or to think, cognitive decline, intellectual disability, and combinations thereof, comprising a step of administering a  Bifidobacterium breve  and/or a cultured material comprising  Bifidobacterium breve  to a subject. 
     
     
         9 . The method according to  claim 8  wherein the  Bifidobacterium breve  is  Bifidobacterium breve  MCC1274 (FERM BP-11175) and/or  Bifidobacterium breve  M-16V (BCCM LMG23729). 
     
     
         10 . A method of using a pharmaceutical composition comprising  Bifidobacterium breve  and/or a cultured material comprising  Bifidobacterium breve , comprising prevention, treatment, and/or improvement of symptoms or diseases resulting from a reduced brain function selected from the group consisting of dementia, depression, schizophrenia, delirium, amnesia, reduced ability to make decisions or judgements, or to think, cognitive decline, intellectual disability, and combinations thereof. 
     
     
         11 . A method of using a food or beverage product comprising  Bifidobacterium breve  and/or a cultured material comprising  Bifidobacterium breve  comprising prevention, treatment, and/or improvement of symptoms or diseases resulting from a reduced brain function selected from the group consisting of dementia, depression, schizophrenia, delirium, amnesia, reduced ability to make decisions or judgements, or to think, cognitive decline, intellectual disability, and combinations thereof. 
     
     
         12 . The method of  claim 10  wherein the  Bifidobacterium breve  is  Bifidobacterium breve  MCC1274 (FERM BP-11175) and/or  Bifidobacterium breve  M-16V (BCCM LMG23729). 
     
     
         13 . The method of  claim 12 , wherein the  Bifidobacterium breve  is  Bifidobacterium breve  MCC1274 (FERM BP-11175) and/or  Bifidobacterium breve  M-16V (BCCM LMG23729).